

DAFTAR PUSTAKA

- Abelson, B., Sun, D., Que, L., Nebel, R.A., Baker, D., Popiel, P., Amundsen, C.L., Chai, T., Close, C., Disanto, M., Fraser, M.O., Kielb, S.J., Kuchel, G., Mueller, E.R., Palmer, M.H., Parker-Autry, C., Wolfe, A.J., Damaser, M.S., 2018. Sex differences in lower urinary tract biology and physiology. *Biol. Sex Differ.* 9, 1–13. <https://doi.org/10.1186/s13293-018-0204-8>
- Aboutaleb H, Gawesh M (2016). *Bladder histopathological changes due to ureteral double-J stenting in 30 patients: A prospective study.* *Eur Urol Suppl.*
- Aggarwal, S.P., Priyadarshi, S., Tomar, V., Yadav, S.S., Gangkak, G., Vyas, N., Agarwal, N., Kumar, U., 2015. A randomized controlled trial to compare the safety and efficacy of Tadalafil and Tamsulosin in relieving double J stent related symptoms. *Adv. Urol.* 2015. <https://doi.org/10.1155/2015/592175>
- Alexander, K., Palinrungi, AM., Palinrungi, MA., Kholis, K., Syahrur, S., Faruk, M., 2020. Effectiveness of Tamsulosin Compared with Mirabegron in Treatment of Double-J Stent-Related Lower Urinary Tract Symptoms. *International J Of Medical Reviews and Case Reports.* 2020. 4(8). 8-13
- Beysens, M., Taily, T.O., 2018. Ureteral stents in urolithiasis. *Asian J. Urol.* 5, 274–286. <https://doi.org/10.1016/j.ajur.2018.07.002>
- Bolla, S.R., Odeluga, N., Jetti, R., 2020. Histology, Bladder, StatPearls. <https://doi.org/31082007>
- Bragg, R., Hebel, D., Vouri, SM., Pitlick, JM., 2014. Mirabegron: a Beta-3 agonist for overactive bladder. *Consult Pharm.* 2014. 29(12). 823-837. doi:10.4140/TCP.n.2014.823
- Cameron, AP., 2016. Medical Management of Neurogenic Bladder with Oral Therapy. *Transl Androl Urol.* 2016. 5(1). 51-62 T.C., Russo, A., Lu, M., 2016. Mucosal signaling in the bladder. *Auton. Neurosci. Basic Clin.* 200, 49–56. <https://doi.org/10.1016/j.autneu.2015.08.009>
- Camtosun A, Bicer S. 2020. The impact of Double J stent on the quality of sexual life and job performance. doi: 10.31083/j.ceog.2020.02.5064
- Chai, T.C., Russo, A., Lu, M., 2016. Mucosal signaling in the bladder. *Auton. Neurosci. Basic Clin.* 200, 49–56. <https://doi.org/10.1016/j.autneu.2015.08.009>



C.R., Siddiqui, E., 2017. Mirabegron for the treatment of overactive der: a review of efficacy, safety and tolerability with a focus on male, rly and antimuscarinic poor-responder populations, and patients with 3 in Asia. *Expert Rev. Clin. Pharmacol.* 10, 131–151. [s://doi.org/10.1080/17512433.2017.1275570](https://doi.org/10.1080/17512433.2017.1275570)

Delnay KM, Stonehill WH, Goldman H, Jukkola AF, Dmochowski RR (1999). *Bladder histological changes associated with chronic indwelling urinary catheter*. J Urol [Internet]. [Updated 1999 Apr;161(4):1106–8; discussion 1108-9; cited 2021 Jan 27]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/10081848>

Fischer K, Louie M, Mucksavage P. 2018. Ureteral Stent Discomfort and Its Management. Current Urology Reports (2018) 19:64 <https://doi.org/10.1007/s11934-018-0818-8>

Gibson, W., MacDiarmid, S., Huang, M., Siddiqui, E., Stölzel, M., Choudhury, N., Drake, M.J., 2017. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur. Urol. Focus 3, 629–638. <https://doi.org/10.1016/j.euf.2017.08.008>

Jabbari, A., Farsh,i A., Sadeghi-Bazargani, H., Hajebrahami., 2015. Validity and reliability of the ureteral stent symptoms questionnaire to Persian Language. J Anal Res Clin Med. 2015. 3(1). 17-22

Janssen, C., Buttyan, R., Seow, C.Y., Jäger, W., Solomon, D., Fazli, L., Chew, B.H., Lange, D., 2017. A Role for the Hedgehog Effector Gli1 in Mediating Stent-induced Ureteral Smooth Muscle Dysfunction and Aperistalsis. Urology 104, 242.e1-242.e8. <https://doi.org/10.1016/j.urology.2017.01.029>

Keay, S.K., Birder, L.A., Chai, T.C., 2014. Evidence for bladder urothelial pathophysiology in functional bladder disorders. Biomed Res. Int. 2014. <https://doi.org/10.1155/2014/865463>

Kelleher, C., Hakimi, Z., Zur, R., Siddiqui, E., Maman, K., Aballéa, S., Nazir, J., Chapple, C., 2018. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis [Figure presented]. Eur. Urol. 74, 324–333. <https://doi.org/10.1016/j.eururo.2018.03.020>

Kemenkes RI, 2020. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19). Gernas 4, 0–115.

Koprowski, C., Kim, C., Modi, P.K., Elsamra, S.E., 2016. Ureteral stent-associated pain: A review. J. Endourol. 30, 744–753. <https://doi.org/10.1089/end.2016.0129>

Lange D., Bidnur, S., Hoag, N., Chew, B.H., 2015. Ureteral stent-associated complications-where we are and where we are going. Nat. Rev. Urol. 12, 17–
<https://doi.org/10.1038/nrurol.2014.340>



, Hsiao, P.J., Chao-Hsiang, C., et all. 2018. Lower Urinary Tract Symptoms associated with Double-J Stent. Urological Science. 2018. 1-7

- Liu, Q., Luo, D., Yang, T., Liao, B., Li, H., Wang, K.J., 2017. Protective Effects of Antimuscarinics on the Bladder Remodeling after Bladder Outlet Obstruction. *Cell. Physiol. Biochem.* 44, 907–919. <https://doi.org/10.1159/000485358>
- Lu, J., Lu, Y., Xun, Y., Chen, F., Wang, S., Cao, S., 2020. Impact of Endourological procedures with or without double-J stent on sexual function: A systematic review and meta-analysis. *BMC Urol.* 20, 1–8. <https://doi.org/10.1186/s12894-020-0582-1>
- Mosayyebi, A., Manes, C., Carugo, D., Somani, B.K., 2018. Advances in Ureteral Stent Design and Materials. *Curr. Urol. Rep.* 19. <https://doi.org/10.1007/s11934-018-0779-y>
- Oh, J.J., Lee, S., Cho, S.Y., Lee, S.W., Cho, M.C., Na, W., Park, J.H., Lee, S.B., Ahh, S., Jeong, C.W., 2017. Effects of naftopidil on double-J stent-related discomfort: A multicenter, randomized, double-blinded, placebo-controlled study. *Sci. Rep.* 7, 1–8. <https://doi.org/10.1038/s41598-017-04505-y>
- Palinggi, E., Palinrungi, M.A., Palinrungi, A.M., Seweng, A., Kholis, K., Syahrir, S., dkk. 2020. Effectiveness of Using Solifenacin Compared to Mirabegron After Double-J Stent Installation for Treatment of Lower Urinary Tract Symptoms (LUTS). *J Med Allied Sci*, 10(2), 115-120)
- Rehman R, Tahir M, Seerwan M. 2016. EFFECT OF TAMSULOSIN ON STENT-RELATED SYMPTOMS; A PROSPECTIVE STUDY. *Professional Med J* 2016;23(1): 114-118.
- Shalaby, E., Ahmed, A.F., Maarouf, A., Yahia I, Ali, M., Ghobish, A., 2013. Clinical Study: Randomized Controlled Trial to Compare the Safety and Efficacy of Tamsulosin, Solifenacin and Combination of Both in Treatment of Double-J Stent-Related Lower Urinary Symptoms. *Advances in Urology*. 2013. h.1-6
- Sharaf, A., Hashim, H., 2017. Profile of Mirabegron in the Treatment of Overactive Bladder: place in Therapy. *Drug Design, Development and Therapy*. 2017. 11. 463-467
- Sellers, D., Chess-Williams, R., Michel, M.C., 2018. Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium. *Naunyn. Schmiedeberg's Arch. Pharmacol.* 391, 675–694. <https://doi.org/10.1007/s00210-018-1510-8>
- Sighinolfi, M.C., Sighinolfi, G.P., Galli, E., Micali, S., Ferrari, N., Mofferdin, A., Bianchi, G., 2015. Chemical and Mineralogical Analysis of Ureteral Stent Installation and Associated Risk Factors. *Urology* 86, 703–706. <https://doi.org/10.1016/j.urology.2015.05.015>
- S.E.L., Mordasini, L., Engeler, D.S., Sauter, R., Schmid, H.P., Abt, D., S. Economic Aspects of Morbidity Caused by Ureteral Stents. *Urol. Int.*



97, 91–97. <https://doi.org/10.1159/000443379>

- Tae, B.S., Cho, S., Jeon, B.J., Choi, H., Park, J.Y., Cho, S.Y., Lee, K.C., Bae, J.H., 2018. Does mirabegron relieve ureteric stent-related discomfort? A prospective, randomized, multicentre study. *BJU Int.* 122, 866–872. <https://doi.org/10.1111/bju.14416>
- Tanidir, Y., Mangir, N., Sahan, A., Sulukaya, M., 2017. Turkish version of the Ureteral Stent Symptoms Questionnaire: linguistic and psychometric validation. *World J. Urol.* 35, 1149–1154. <https://doi.org/10.1007/s00345-016-1958-4>
- Vogt, B., Chokri, I., 2020. Histological Inflammation in Human Ureter either Healthy or Fitted with Double-Pigtail Stent or a Thin 0.3 F Suture Thread: A Preliminary Study. *Adv. Urol.* 2020. <https://doi.org/10.1155/2020/1204897>
- Wang, G., McKenney, J.K., 2019. Urinary Bladder Pathology: World Health Organization Classification and American Joint Committee on Cancer Staging Update. *Arch. Pathol. Lab. Med.* 143, 571–577. <https://doi.org/10.5858/arpa.2017-0539-RA>
- White, W.B., Siddiqui, E., Tat, T., Franks, B., Schermer, C.R., 2018. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. *J. Am. Soc. Hypertens.* 12, 768-778.e1. <https://doi.org/10.1016/j.jash.2018.08.001>
- Young, A., 2017. The physiology of wound healing. *Surgery* 35, 473–477. <https://doi.org/10.1016/j.mpsur.2017.06.004>
- Zhou, L., Cai, X., Li, H., Wang, K., 2015. Effects of α -Blockers, Antimuscarinics, or Combination Therapy in Relieving Ureteral Stent-Related Symptoms: A Meta-Analysis. *J. Endourol.* 29, 650–656. <https://doi.org/10.1089/end.2014.0715>
- Ziemba, J.B., Ludwig, W.W., Ruiz, L., Carvalhal, E., Matlaga, B.R., 2017. Preventing the Forgotten Ureteral Stent by Using a Mobile Point-of-Care Application. *J. Endourol.* 31, 719–724. <https://doi.org/10.1089/end.2017.0118>
- Zumstein, V., Betschart, P., Albrich, W.C., Buhmann, M.T., Ren, Q., Schmid, H.-P., Abt, D., 2017. Biofilm formation on ureteral stents - Incidence, clinical impact, and prevention. *Swiss Med. Wkly.* <https://doi.org/10.4414/smw.2017.14408>



Lampiran 1



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpCK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 794/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 12 Desember 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22100627		No Sponsor	
Peneliti Utama	dr. Hans Alfonso		Sponsor	
Judul Peneliti	Efek Pemberian Agonis Reseptor Adrenergik ?3 (Mirebegron) Terhadap Derajat Inflamasi Mukosa Kandung Kemih Pada Penderita Paska Pemasangan Ureteral Stent			
No Versi Protokol	2	Tanggal Versi	7 Desember 2022	
No Versi PSP	2	Tanggal Versi	7 Desember 2022	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar			
Jenis Review	☐ Exempted ☐ Expedited ☒ Fullboard Tanggal 3 Nopember 2022		Masa Berlaku 12 Desember 2022 sampai 12 Desember 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)		Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)		Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Menyerahkan laporan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Menyerahkan laporan pelanggaran terhadap semua peraturan yang ditentukan



Lampiran 2

BIODATA PENULIS



I. DATA PRIBADI

Nama lengkap : dr. Hans Alfonso
Tempat/ tanggal lahir : Ujung Pandang, 13 April 1991
Jenis Kelamin : Laki-laki
Status kewarganegaraan : Indonesia
Agama : Katolik
Alamat Korespondensi : Jln. Veteran Selatan no. 144,
Kecamatan Mamajang/Kota Makassar
Sulawesi Selatan
Telepon : 085396786288
E-Mail : hansthioritz@yahoo.com

II. RIWAYAT KELUARGA

Nama orang tua
Ayah : Ir. A. Jimmy Thioritz
Ibu : Ellen Lasapu
Alamat : Jln. Veteran Selatan no. 144,
Kecamatan Mamajang/Kota Makassar
Sulawesi Selatan

III. RIWAYAT PENDIDIKAN

1996 – 2002 : SD Katolik Mamajang I Makassar
2002 – 2005 : SMP Katolik Rajawali Makassar
2005 – 2008 : SMA Katolik Rajawali Makassar
– 2013 : Program Studi Sarjana Kedokteran Fakultas Kedokteran
Universitas Hasanuddin



2013 – 2015 : Program Studi Profesi Dokter Fakultas Kedokteran
Universitas Hasanuddin

2019 – 2023 : Program Studi Ilmu Bedah Fakultas Kedokteran Universitas
Hasanuddin

IV. RIWAYAT ORGANISASI

Anggota IDI

V. RIWAYAT PENELITIAN DAN PUBLIKASI

1. Hubungan Anemia terhadap dengan Kadar HbA1C pada Penderita Diabetes
Melitus Tipe II di Rumah Sakit Labuang Baji Makassar

Makassar, 29 Mei 2023



HANS ALFONSO



Lampiran 3. Data Peneltiian

No	JK	BB	TB	IMT	SUKU	PKJ	Umur	KODE SAMPEL	PA	
									Pre Stent	Post Stent
1	P	60	158	24.03	Bugis	IRT	53	AU2	1	0
2	P	70	158	28.04	Banjar	Wiraswasta	36	AW1	0	2
3	P	50	155	20.8	Bugis	IRT	55	AW2	2	0
4	P	40	150	17.7	Bugis	IRT	23	AA2	0	1
5	L	104	162	39.6	Bugis	PNS	25	AA4	1	1
6	P	38	150	16.8	Bugis	Pelajar	18	AW3	0	1
7	P	54	160	21.09	Toraja	IRT	60	AW5	0	1
8	L	66	159	21.7	Bugis	Wiraswasta	48	AU7	0	1
9	L	80	167	28.7	Mks	PNS	57		0	1
10	L	75	165	27.5	Mks	PNS	45		0	1
11	P	55	155	22.9	Mks	IRT	36		0	2
							41.45454545		0.363636364	1
1	L	62	165	22.7	Toraja	Wiraswasta	36	BW2	0	4
2	P	60	163	22.5	Bugis	Karyawan	21	BU1	2	4
3	L	67	168	23.7	Bugis	Wiraswasta	34	BU2	0	3
4	L	66	160	25.7	Bugis	Wiraswasta	30	BW3	0	4
5	L	70	167	25.09	Toraja	IRT	48	BU3	1	3
6	L	48	165	17.6	Bugis	Wiraswasta	42	BW4	1	4
7	P	90	160	35.15	Mandar	IRT	38	BU4	1	2
8	L	53	167	19.0	bUGIS	Wiraswasta	31	BA1	0	3
9	P	60	150	26.6	Bugis	IRT	67	BU5	0	4
10	L	76	170	26.2	Bugis	TNI	52	BW6	2	0
11	P	44	160	17.1	Bugis	Wiraswasta	24	BA3	0	3
12	L	52	160	20.3	Toraja	PNS	56	BW7	0	4
							39.91666667	Mean	0.583333333	3.166666667
1	L	72	165	26.4	Bugis	Petani	41	CU1	0	4
2	L	55	167	19.4	Bugis	Karyawan	25	CU2	0	0
3	L	60	170	20.7	Toraja	Karyawan	25	CW2	1	1
4	P	65	150	28.8	Bugis	IRT	61	CU3	0	2
				34.6	Bugis	PNS	42	CU4	0	3
				21.6	Bugis	IRT	54	CA2	1	2
				21.8	Toraja	IRT	34	CA3	1	2
				23.1	Bugis	Karyawan	36	CA4	2	2



9	P	55	155	22.8	Bugis	IRT	53	CA5	1	3
10	L	61	160	23.8	Bugis	Wiraswasta	40	CW4	0	0
11	L	70	169	24.5	Bugis	Karyawan	31	CU5	0	4
12	L	62	170	21.4	Bugis	Karyawan	37	CU6	0	4
13	L	63	165	23.1	Toraja	Supir	42	CW5	1	2
14	L	60	165	22.03	Bugis	Petani	43	CW6	0	1
15	P	60	150	26.6	Mks	IRT	53		0	2
16	P	60	163	22.5	Mks	IRT	55		0	1
17	P	67	168	23.7	Mks	karyawan	45		1	1
							42.17647059	Mean	0.470588235	2

